Wehring, Heidi J .
Elsobky, Teresa
McEvoy, Joseph P.
Vyas, Gopal
Richardson, Charles M.
McMahon, Robert P.
DiPaula, Bethany A.
Liu, Fang
Sullivan, Kelli
Buchanan, Robert W.
Feldman, Stephanie
McMahon, Elizabeth M.
Kelly, Deanna L.
Funding for this research was provided by:
National Institute of Mental Health (1R21MH091184-01A1)
National Institute on Drug Abuse (K23DA034034)
Article History
First Online: 3 May 2017
Compliance with Ethical Standards
:
: Deanna L. Kelly, PharmD, is a consultant for Lundbeck and XOMA. Joseph P. McEvoy, MD, is a consultant for Ameritox, Alkermes, Envivo, Jazz, Otsuka, and Merck. Robert P. McMahon, PhD, is a consultant for Amgen, Inc. Robert W. Buchanan, MD, is a Data Safety Monitoring Board member for Otsuka and Pfizer. He consulted with Abbott and is affiliated with Amgen, Bristol-Meyers Squibb, EnVivo, Omeros, and Pfizer. He is also part of the advisory boards of Abbott; Amgen; EnVivo; Janssen Pharmaceutical, Inc.; NuPathe, Inc.; Pfizer; Roche; and Takeda. The remaining authors declare no conflicts of interest.
: 1R21MH091184-01A1 (PI Deanna L. Kelly), funded by the National Institute of Mental Health, Bethesda, MD.K23DA034034 (PI Heidi J. Wehring), funded by the National Institute on Drug Abuse, Bethesda, MD.
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional research boards and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
: This study was approved by the University of Maryland, Baltimore, the State of Maryland Department of Health and Mental Hygiene, and Duke University IRBs and performed in compliance with Declaration of Helsinki.
: Informed consent was obtained from all individual included participants.